Posts Tagged ‘GLP-1 agonists’

We have mixed feelings about a new report in JAMA this week about GLP-1 agonists and the associated risk of gastrointestinal adverse events. On one hand, this is helpful data. It is a reminder that despite all of the sensational reporting about “weight loss miracles,” these drugs are serious medicines that require careful prescribing and […]

People have “lots of interest” in the effects of GLP-1 treatment for obesity on body composition, reports endocrinologist Daniel Drucker from EASD in Hamburg. Judging from clickbait headlines about semaglutide, we suspect public interest in this question is strong as well. So that makes data presented at EASD from the SURPASS study on muscle composition […]

It’s enough to make our heads spin. The incredible vibrancy in obesity research is on full display at the meeting of the European Association for the Study of Diabetes – EASD 2023 in Hamburg. Today, it starts with a bang. Successive presentations on multi-agonists for obesity are scheduled this afternoon at EASD. But the abstracts […]

In the midst of an argument for lifestyle as the “cornerstone” for dealing with obesity, Frank Hu recently made a point with which we agree. He expressed the importance of GLP-1 agonists for obesity and warned that issues with access could bring wider health disparities. Because pricing of these drugs, health insurance, and weight-related biases […]

“If you thought that GLP-1 agonists would replace bariatric surgery you are wrong.” Neil Floch is not alone in saying this and new research adds to the reasons we suspect that he is right. In JAMA Surgery, Jessica Mok and colleagues tell us that one plus one equals three with the combination of bariatric surgery […]

The emergence of advanced medicines for obesity is teaching us a lot about the overlapping mechanisms that drive desires for alcohol, food, and more. Desire, it seems, is more than just a feeling. It is the product of biological processes that our bodies regulate. But those processes can clearly go astray, and desire for food, […]

Insights surface when we take the time to listen to people living with obesity. Yesterday, Ro and the Obesity Action Coalition released results from a study of the thoughts and feelings people are having about obesity, weight loss, and the new GLP-1 medicines. There’s a lot to think about in these results – about motivations […]

This is a merger that has taken decades – the merger of obesity and diabetes. Ethan Sims first coined the term diabesity in 1973. Even five decades ago, the coincidence of diabetes and obesity was unmistakable, but the standards of care for obesity and diabetes did not reflect the recognition of obesity as anything other […]

We would classify this as a report of a side effect. But it’s not really an adverse event. It seems that for some people, the use of semaglutide has prompted less alcohol use. In the New York Times, Dani Blum describes the experience of one patient: “In August 2022, Eva Monsen’s endocrinologist prescribed Ozempic [semaglutide] […]

Move over, Novo Nordisk and Eli Lilly. Amgen wants a piece of the action in obesity treatment. With some obvious pride of accomplishment, Amgen unveiled results from a phase 1 study of its dual action conjugate on Saturday. This new experimental drug, AMG 133, is a molecule that combines peptides to activate GLP-1 receptors (as […]